Long-term incobotulinumtoxinA treatment for chronic sialorrhea: Efficacy and safety over 64 weeks
- PMID: 31794936
- DOI: 10.1016/j.parkreldis.2019.11.024
Long-term incobotulinumtoxinA treatment for chronic sialorrhea: Efficacy and safety over 64 weeks
Abstract
Background: Botulinum neurotoxin (BoNT) is an effective treatment for chronic sialorrhea; however, reliable and robust evidence supporting long-term efficacy and safety is lacking. This study investigated the efficacy and safety of repeated incobotulinumtoxinA injections for chronic sialorrhea over 64 weeks.
Methods: Adults with sialorrhea were randomized (2:2:1) to incobotulinumtoxinA 75 U, incobotulinumtoxinA 100 U (n = 74 each), or placebo (n = 36) in the double-blind, placebo-controlled main period (NCT02091739). Eligible subjects entered the extension period and received dose-blinded incobotulinumtoxinA 75 or 100 U in three further 16±2-week injection cycles. Efficacy and safety assessments in subjects who received incobotulinumtoxinA throughout the study included unstimulated salivary flow rate (uSFR), subjects' Global Impression of Change Scale (GICS), Drooling Severity and Frequency Scale (DSFS), modified Radboud Oral Motor Inventory for Parkinson's Disease (mROMP) drooling, speech, and swallowing symptom scores, and incidence of adverse events (AEs).
Results: In total, 173/184 subjects (94%) completed the main period and entered the extension period; 141 subjects received incobotulinumtoxinA 75 U (n = 69) or 100 U (n = 72) in both periods. Mean uSFR decreased consistently with repeated incobotulinumtoxinA 75 and 100 U treatment and by -0.16 and -0.17, respectively, at the end-of-study visit. Subjects' GICS, DSFS, and mROMP drooling scores also improved at all assessments. mROMP speech and swallowing scores remained stable. The most common treatment-related AEs during the extension period were dry mouth (4.4% and 11.1%) and dysphagia (1.5% and 4.2%).
Conclusions: Data support long-term efficacy and safety of repeated incobotulinumtoxinA treatment for sialorrhea, with no additional safety concerns reported over 64 weeks.
Keywords: Botulinum toxin; Drooling; IncobotulinumtoxinA; Parkinson's disease/Parkinsonism; Sialorrhea.
Copyright © 2019. Published by Elsevier Ltd.
Similar articles
-
SIAXI: Placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea.Neurology. 2019 Apr 23;92(17):e1982-e1991. doi: 10.1212/WNL.0000000000007368. Epub 2019 Mar 27. Neurology. 2019. PMID: 30918101 Free PMC article. Clinical Trial.
-
Efficacy and safety of incobotulinumtoxinA in post-stroke upper-limb spasticity in Japanese subjects: results from a randomized, double-blind, placebo-controlled study (J-PURE).J Neurol. 2020 Jul;267(7):2029-2041. doi: 10.1007/s00415-020-09777-5. Epub 2020 Mar 26. J Neurol. 2020. PMID: 32219557 Free PMC article. Clinical Trial.
-
Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson's disease: a prospective double-blind trial.Mov Disord. 2012 Feb;27(2):219-26. doi: 10.1002/mds.23929. Epub 2011 Sep 1. Mov Disord. 2012. PMID: 21887710 Clinical Trial.
-
A critical review of incobotulinumtoxinA in the treatment of chronic sialorrhea in pediatric patients.Expert Rev Neurother. 2021 Oct;21(10):1059-1068. doi: 10.1080/14737175.2021.1979959. Epub 2021 Oct 4. Expert Rev Neurother. 2021. PMID: 34516331 Review.
-
The effectiveness and safety of botulinum toxin injections for the treatment of sialorrhea with Parkinson's disease: a systematic review and meta-analysis.BMC Pharmacol Toxicol. 2023 Oct 12;24(1):52. doi: 10.1186/s40360-023-00694-7. BMC Pharmacol Toxicol. 2023. PMID: 37828600 Free PMC article.
Cited by
-
Autonomic Dysfunction in Parkinson's Disease.Neurotherapeutics. 2020 Oct;17(4):1464-1479. doi: 10.1007/s13311-020-00897-4. Neurotherapeutics. 2020. PMID: 32789741 Free PMC article. Review.
-
Oral health effects of botulinum toxin treatment for drooling: a systematic review.Med Oral Patol Oral Cir Bucal. 2021 Mar 1;26(2):e172-e180. doi: 10.4317/medoral.24101. Med Oral Patol Oral Cir Bucal. 2021. PMID: 33340083 Free PMC article.
-
Recommendations for a paradigm shift in approach to increase the recognition and treatment of sialorrhea in Parkinson's disease.Clin Park Relat Disord. 2023 Oct 11;9:100223. doi: 10.1016/j.prdoa.2023.100223. eCollection 2023. Clin Park Relat Disord. 2023. PMID: 38021341 Free PMC article. Review.
-
Botulinum neurotoxin type A in the interdisciplinary treatment of sialorrhea in adults and children-update and practice recommendations.Front Neurol. 2023 Dec 13;14:1275807. doi: 10.3389/fneur.2023.1275807. eCollection 2023. Front Neurol. 2023. PMID: 38162447 Free PMC article. Review.
-
Use of Botulinum Neurotoxin in Parkinson's Disease: A Critical Appraisal.Toxins (Basel). 2021 Jan 25;13(2):87. doi: 10.3390/toxins13020087. Toxins (Basel). 2021. PMID: 33503872 Free PMC article. Review.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical